AbbVie announced a $1.4 billion investment for a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, its largest single-site capital commitment.
Construction begins in 2026 and completes by end of 2028.
Project creates 734 permanent jobs over four years (engineers, scientists, operators) and over 2,000 construction jobs.
Facility focuses on injectable therapies for immunology, neuroscience, and oncology, integrating AI and advanced tech.
Part of AbbVie's $100 billion U.S. R&D and capital investment commitment over next decade.
No sources mention completion during Trump's term; timeline ends 2028.